» Articles » PMID: 12033365

Content Uniformity and Dose Uniformity: Current Approaches, Statistical Analyses, and Presentation of an Alternative Approach, with Special Reference to Oral Inhalation and Nasal Drug Products

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2002 May 30
PMID 12033365
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

This article reviews current and proposed approaches to content uniformity testing. In addition, the article proposes an approach that allows regulatory agencies and compendia to clearly state allowable consumer risk. Further, the article suggests that producers be allowed to control producer risk through selection of numbers of units and testing tiers. The approach facilitates risk communication to practitioners and patients/consumers, which is impeded with current approaches, and reduces regulatory and compendial burden.

Citing Articles

Chromatographic fingerprinting of ipratropium and fenoterol in their novel co-formulated inhaler treating major respiratory disorders; application to delivered dose uniformity testing along with greenness and whiteness assessment.

Ali S, Saad S, Fayed A, Marzouk H BMC Chem. 2024; 18(1):157.

PMID: 39192312 PMC: 11350986. DOI: 10.1186/s13065-024-01265-5.


On the Feasibility of Rugose Lipid Microparticles in Pressurized Metered Dose Inhalers with Established and New Propellants.

Minootan Z, Wang H, Connaughton P, Lachacz K, Carrigy N, Ordoubadi M AAPS PharmSciTech. 2024; 25(4):82.

PMID: 38600288 DOI: 10.1208/s12249-024-02776-z.


Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.

Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S Pharmaceutics. 2022; 14(7).

PMID: 35890327 PMC: 9325229. DOI: 10.3390/pharmaceutics14071432.


Study of the applicabilty of content uniformity and dissolution variation test on ropinirole hydrochloride tablets.

Vranic E, Uzunovic A Bosn J Basic Med Sci. 2008; 8(2):193-200.

PMID: 18498274 PMC: 5698354. DOI: 10.17305/bjbms.2008.2981.


Oral dosage form performance tests: new dissolution approaches.

Hauck W, Foster T, Sheinin E, Cecil T, Brown W, Marques M Pharm Res. 2005; 22(2):182-7.

PMID: 15783064 DOI: 10.1007/s11095-004-1184-4.

References
1.
Hauck W, Shaikh R . Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content. J Biopharm Stat. 2002; 11(4):335-46. View

2.
Williams R, Adams W, Chen M, Hare D, Hussain A, Lesko L . Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee. Eur J Drug Metab Pharmacokinet. 2000; 25(1):7-12. DOI: 10.1007/BF03190049. View

3.
McPherson K . Statistics: the problem of examining accumulating data more than once. N Engl J Med. 1974; 290(9):501-2. DOI: 10.1056/NEJM197402282900907. View

4.
Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

5.
Esinhart J, Chinchilli V . Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals. Int J Clin Pharmacol Ther. 1994; 32(1):26-32. View